If you are interested in learning more about one of our ongoing clinical trials, please feel free to call our Clinical Research Program at 520-320-2147.
Epilepsy Clinical Trial – Now Enrolling
Lennox-Gastaut Syndrome: Zogenix Study
A program of clinical studies that will assess whether an investigational drug called ZX008 can reduce the number of seizures experienced by children and young adults.
Learn more at ClinicalTrials
Identifier (NCT): NCT03276286
Pediatric Migraine
Eli Lilly: PIONEER-PEDS1 Study
For this clinical research study, we are seeking children and teenagers ages six to less than 18 with a history of migraine headaches for more than six months. The purpose of the PIONEER-PEDS1 Study is to evaluate the safety and effectiveness of a study medicine called lasmiditan in reducing the pain of migraine headaches. In this study, lasmiditan will be compared to a placebo, which looks the same as lasmiditan but does not contain any active medicine. You and your child will not know whether your child receives lasmiditan or the placebo. This allows researchers to accurately evaluate the effects of the study medicine.
The PIONEER-PEDS1 Study consists of a screening visit, enrollment visit, treatment period and end-of-study visit. The screening and enrollment visits are used to determine whether your child qualifies to participate in the study. Once enrolled, they are randomly assigned to a treatment group. The treatment period may last up to 12 weeks, during which your child will be asked to treat one migraine headache with the study medicine. Your child will use an e-Diary (an app on a device) not only to help identify the right migraine to treat, but also to guide them through taking the blinded study medicine and reporting how they feel.
Eli-Lilly: Rebuild-2 Study
For this clinical research study, we are seeking children and teenagers ages 12 to 17 who have a diagnosis of chronic migraine. The goal of the REBUILD-2 Study is to investigate a new medicine, called galcanezumab, for preventing migraine headaches. In this study, galcanezumab will be compared to a placebo, which looks the same as galcanezumab but does not contain any active medicine. You will not know whether you receive galcanezumab or the placebo during the first treatment period
(known as a double-blind period, because neither you nor the study doctor will know which treatment you get)—this allows researchers to learn if the study medicine is working. During the second treatment period of the study (known as an open-label period, because you and the study doctor will know what treatment you get), you will receive galcanezumab. Participation in the REBUILD-2 Study lasts about 18 months.
Eli-Lilly: Rebuild-1 Study
For this clinical research study, we are seeking children and teenagers ages six to 17 who have had a history of migraine for at least six months. The goal of the REBUILD-1 Study is to investigate a new medicine, called galcanezumab, for preventing migraine headaches. In this study, galcanezumab will be compared to a placebo, which looks the same as galcanezumab but does not contain any active medicine. You will not know whether you are receiving galcanezumab or the placebo during the first treatment period (known as a double-blind period, because neither you nor the study doctor will know which treatment you receive)—this allows researchers to learn if the study medicine is working.
During the second treatment period of the study (known as an open-label period, because you and the study doctor will know what treatment you get), you will receive galcanezumab. Participation in the REBUILD-1 Study lasts about 18 months.